Loading live market data…

IDEXX Laboratories, Inc.

NASDAQ:IDXX

$540.68 USD

-$23.53 (-4.17%)

Volume
780.14K
Average Volume
657.72K
Market Capitalization
$42.65B
P/E Ratio
39.55
Dividend Yield
0.00%
Price Target
$775.00
Year High
$769.98
Year Low
$506.91
Day High
Day Low
Payout Ratio
$0.00
Current Ratio
$1.12
Source Headline
These 3 Water ETFs Could be Quiet Winners From Infrastructure Spending

Data centers receive sharp criticism for their high water usage, but the impact on the broader water industry and for investors is also about infrastructure bottlenecks, regulation, and emerging technologies, among other things. Utilities companies must navigate significant changes when hyperscalers enter their territory—in some cases, a new data center operator may immediately become one of the largest customers in the region.

marketbeat.com - 2026-07-14 10:45:22

Buy 3 AI-Led Medical Devices Laggards of 1H Set to Gather Pace in 2H

ISRG, IDXX and ALC are three AI-driven medical device laggards with strong business momentum and improving earnings estimates for a potential 2H rebound.

zacks.com - 2026-07-14 08:41:07

ALC vs. IDXX: Which Stock Is the Better Value Option?

Investors looking for stocks in the Medical - Instruments sector might want to consider either Alcon (ALC) or Idexx Laboratories (IDXX). But which of these two companies is the best option for those looking for undervalued stocks?

zacks.com - 2026-07-07 12:41:10

IDEXX Laboratories to Release 2026 Second Quarter Financial Results

WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2026 second quarter financial results for Tuesday, August 4, 2026, before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. ET on that day. Individuals can access a live webcast of the conference call, transcript of prepared remarks, and the Q2 2026 Earnings Snapshot through a link on the IDEXX websi.

businesswire.com - 2026-07-01 16:00:00

Why Idexx Laboratories (IDXX) is a Top Growth Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

zacks.com - 2026-06-30 10:46:22

Is the Options Market Predicting a Spike in IDEXX Laboratories Stock?

Investors need to pay close attention to IDXX stock based on the movements in the options market lately.

zacks.com - 2026-06-29 11:06:05

IDEXX Laboratories Inc (IDXX) Stock Down 4.7% -- Now Undervalued? GF Score: 96/100

On June 17, 2026, IDEXX Laboratories Inc (IDXX) shares fell 4.7% to $546.09. The stock's current price is within a 52-week range of $506.91 to $769.98, reflecti

gurufocus.com - 2026-06-17 18:11:00

Here's Why Idexx Laboratories (IDXX) is a Strong Momentum Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

zacks.com - 2026-06-11 10:52:04

Here's Why Idexx Laboratories (IDXX) is a Strong Growth Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

zacks.com - 2026-06-09 10:46:12

Idexx (IDXX) Down 3.2% Since Last Earnings Report: Can It Rebound?

Idexx (IDXX) reported earnings 30 days ago. What's next for the stock?

zacks.com - 2026-06-04 12:36:34

IDEXX Laboratories Touts AI Push, inVue Dx Momentum at Stifel Conference

IDEXX Laboratories NASDAQ: IDXX President and CEO Michael Erickson used a Stifel investor conference appearance to emphasize the company's innovation pipeline, expanding commercial reach and growing use of software and artificial intelligence across veterinary diagnostics.

marketbeat.com - 2026-05-30 07:02:41

IDEXX Laboratories, Inc. (IDXX) Presents at Stifel Jaws & Paws Conference 2026 Transcript

IDEXX Laboratories, Inc. (IDXX) Presents at Stifel Jaws & Paws Conference 2026 Transcript

seekingalpha.com - 2026-05-27 13:27:05

IDEXX Expands Fecal Dx Antigen Testing Platform with Taeniid Tapeworm Detection

WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX expands Fecal Dx™ antigen testing with taeniid tapeworm detection for broader intestinal parasite screening in wellness and sick-pet care.

businesswire.com - 2026-05-26 07:00:00

IDEXX SDMA Now Integrated into the Most Common Catalyst Chemistry Profiles

WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX integrates SDMA into most common Catalyst chemistry profiles, enabling earlier detection of kidney disease through routine in‑clinic testing.

businesswire.com - 2026-05-19 07:00:00

The Biology Came First.

MindWalk Holdings Corp. (NASDAQ: HYFT) today released a systematic report identifying over 20 discovery-originated drug candidates with documented origins in a

gurufocus.com - 2026-05-18 09:00:00

IDEXX Laboratories to Present at Stifel Conference and Announces 2026 Investor Day

WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced that Mike Erickson, President and Chief Executive Officer, will participate in a fireside chat at the Stifel Jaws & Paws Conference on Wednesday, May 27, 2026 from 10:55 am – 11:25 am (ET). A live audio webcast of the presentation will be available through a link on the IDEXX website, www.idexx.com/investors. An archived edition of the presentation will b.

businesswire.com - 2026-05-14 16:34:00

IDEXX Laboratories Inc (IDXX) Shares Fall 5.0% -- What GF Score of 99 Tells Investors

On May 11, 2026, IDEXX Laboratories Inc (IDXX) shares fell 5.0% to a current price of $532.00. This decline comes amid a challenging performance period for the

gurufocus.com - 2026-05-11 19:52:00

IDEXX Laboratories, Inc. (IDXX) Q1 2026 Earnings Call Transcript

IDEXX Laboratories, Inc. (IDXX) Q1 2026 Earnings Call Transcript

seekingalpha.com - 2026-05-05 14:11:13

IDEXX Stock Up on Q1 Earnings & Revenue Beat, Margins Rise, '26 View Up

IDXX rides strong on Q1 beats with rising margins; lifts 2026 outlook as diagnostics growth and innovation momentum fuel performance.

zacks.com - 2026-05-05 11:31:21

Idexx (IDXX) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

The headline numbers for Idexx (IDXX) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

zacks.com - 2026-05-05 10:30:42

Idexx Laboratories Raises Guidance On Higher Clinical Visits, Diagnostic Frequency

Idexx Laboratories Inc (NASDAQ:IDXX) shares are up on Tuesday as the company recently announced strong first-quarter results, showcasing a 14% revenue growth.

benzinga.com - 2026-05-05 10:20:28

Idexx Laboratories (IDXX) Q1 Earnings and Revenues Surpass Estimates

Idexx Laboratories (IDXX) came out with quarterly earnings of $3.47 per share, beating the Zacks Consensus Estimate of $3.42 per share. This compares to earnings of $2.96 per share a year ago.

zacks.com - 2026-05-05 08:45:30

IDEXX Laboratories Announces First Quarter Results

WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced first quarter results. First Quarter Results The Company reports revenues of $1,141 million for the first quarter of 2026, an increase of 14% as reported and 11% organic, driven by Companion Animal Group ("CAG") growth of 15% as reported and 12% organic. First quarter earnings per diluted share (“EPS”) were $3.47, an increase of 17% as reported and 15% on a c.

businesswire.com - 2026-05-05 06:30:00

GMED vs. IDXX: Which Stock Should Value Investors Buy Now?

Investors interested in Medical - Instruments stocks are likely familiar with Globus Medical (GMED) and Idexx Laboratories (IDXX). But which of these two stocks is more attractive to value investors?

zacks.com - 2026-05-04 12:40:32

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

zacks.com - 2026-05-04 09:55:20

Here's How IDEXX Laboratories Is Placed Ahead of Q1 Earnings

IDXX heads into Q1 earnings with strong growth forecasts, steady estimate beats, and momentum in diagnostics and recurring revenue streams.

zacks.com - 2026-05-01 10:11:20

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

zacks.com - 2026-04-30 09:56:13

Comerica Bank Sells 9,639 Shares of IDEXX Laboratories, Inc. $IDXX

Comerica Bank lessened its holdings in IDEXX Laboratories, Inc. (NASDAQ: IDXX) by 35.5% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 17,493 shares of the company's stock after selling 9,639 shares during the quarter. Comerica Bank's holdings in IDEXX Laboratories

defenseworld.net - 2026-04-29 14:41:17

IDXX DCF Analysis: Intrinsic Value $398 vs Price $568

On April 29, 2026, we take a closer look at the DCF analysis for IDEXX Laboratories Inc (IDXX). The company has experienced a price performance of -0.1% over th

gurufocus.com - 2026-04-29 07:31:00

Idexx Laboratories (IDXX) Reports Next Week: Wall Street Expects Earnings Growth

Idexx (IDXX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

zacks.com - 2026-04-28 11:07:51

Stryker to Report Q1 Earnings: What's in Store for the Stock?

SYK heads into Q1 earnings with strong procedure demand and robotic surgery growth, but tariff and cost pressures may test margins.

zacks.com - 2026-04-28 09:50:31

University of New England launches new Institute of Public and Planetary Health in honor of philanthropist and IDEXX Founder David Evans Shaw

A $5 million gift from the storied entrepreneur, activist, and impact investor will advance the University of New England's work at the intersection of environmental and human health while boosting Maine's research and workforce landscape across sectors. A $5 million gift from the storied entrepreneur, activist, and impact investor will advance the University of New England's work at the intersection of environmental and human health while boosting Maine's research and workforce landscape across sectors.

globenewswire.com - 2026-04-27 11:40:00

IDEXX Laboratories, Inc. $IDXX Shares Sold by AEGON ASSET MANAGEMENT UK Plc

AEGON ASSET MANAGEMENT UK Plc reduced its position in IDEXX Laboratories, Inc. (NASDAQ: IDXX) by 4.6% in the undefined quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 26,068 shares of the company's stock after selling 1,247 shares during the quarter. AEGON ASSET MANAGEMENT UK

defenseworld.net - 2026-04-26 03:09:00

Is IDXX Overvalued? DCF Says Worth $398

On April 23, 2026, we delve into the DCF analysis for IDEXX Laboratories Inc (IDXX), a company currently priced at $578.35. Over the past year, IDXX has demonst

gurufocus.com - 2026-04-23 07:04:00

IDEXX Laboratories Vs. Zoetis: A Pre-Earnings Comparison

Idexx Laboratories, Inc. and Zoetis Inc. are dominant players in animal health, but IDXX outperforms due to superior capital efficiency and recurring revenue flywheel. ZTS trades at a much lower valuation with solid margins and a dependable pipeline, but requires catalysts—like EPS beats or new approvals—for rerating in 2026. IDXX commands a premium valuation, driven by high ROIC (37–49%) and robust growth in diagnostics, notably its Cancer DX test and InVue DX instrument adoption.

seekingalpha.com - 2026-04-22 11:27:13

Why Idexx Laboratories (IDXX) is a Top Momentum Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

zacks.com - 2026-04-16 10:51:11

Assetmark Inc. Purchases 1,518 Shares of IDEXX Laboratories, Inc. $IDXX

Assetmark Inc. lifted its position in shares of IDEXX Laboratories, Inc. (NASDAQ: IDXX) by 3.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 52,769 shares of the company's stock after acquiring an additional 1,518 shares during the period.

defenseworld.net - 2026-04-15 03:17:46

Get IDXX Insider Trade Alerts

IDXX Price Target Summary

Last Month

$0.00

0 analysts

Last Quarter

$640.00

1 analysts

Last Year

$759.53

17 analysts

All Time

$650.82

28 analysts

IDXX Recent Analyst Grades

Date Analyst Firm Action Previous Grade New Grade
2026-04-28 UBS Maintain Neutral Neutral
2026-03-31 Stifel Maintain Buy Buy
2026-02-09 Piper Sandler Maintain Neutral Neutral
2026-02-05 Barclays Maintain Overweight Overweight
2026-02-03 UBS Maintain Neutral Neutral
2026-02-03 BTIG Maintain Buy Buy
2025-11-04 JP Morgan Maintain Overweight Overweight
2025-11-04 BTIG Maintain Buy Buy
2025-11-04 Morgan Stanley Maintain Overweight Overweight
2025-11-04 UBS Maintain Neutral Neutral
2025-10-31 Stifel Upgrade Hold Buy
2025-08-15 Morgan Stanley Maintain Overweight Overweight
2025-08-11 Piper Sandler Maintain Neutral Neutral
2025-08-04 Morgan Stanley Maintain Overweight Overweight
2025-08-04 JP Morgan Maintain Overweight Overweight
2025-07-29 Morgan Stanley Maintain Overweight Overweight
2025-07-17 Leerink Partners Maintain Outperform Outperform
2025-07-02 Stifel Maintain Hold Hold
2025-06-11 Leerink Partners Maintain Outperform Outperform
2025-05-19 Stifel Maintain Hold Hold
2025-05-05 Morgan Stanley Maintain Overweight Overweight
2025-05-01 Stifel Maintain Hold Hold
2025-04-21 B of A Securities Maintain Neutral Neutral
2025-04-15 Morgan Stanley Maintain Overweight Overweight
2025-04-14 Stifel Maintain Hold Hold
2025-02-28 Stifel Maintain Hold Hold
2025-02-10 Piper Sandler Maintain Neutral Neutral
2025-02-04 Barclays Maintain Overweight Overweight
2025-02-04 B of A Securities Maintain Neutral Neutral
2025-02-04 Morgan Stanley Maintain Overweight Overweight
2025-02-03 Stifel Maintain Hold Hold
2025-01-29 Morgan Stanley Maintain Overweight Overweight
2024-11-04 Piper Sandler Maintain Neutral Neutral
2024-11-04 Barclays Maintain Overweight Overweight
2024-10-11 JP Morgan Maintain Overweight Overweight
2024-10-10 Stifel Maintain Hold Hold
2024-08-14 Piper Sandler Maintain Neutral Neutral
2024-06-24 Stifel Maintain Hold Hold
2024-05-14 Morgan Stanley Maintain Overweight Overweight
2024-05-02 Barclays Maintain Overweight Overweight
2024-02-06 Barclays Maintain Overweight Overweight
2024-02-06 JP Morgan Maintain Overweight Overweight
2024-01-30 Piper Sandler Downgrade Overweight Neutral
2024-01-17 Goldman Sachs Maintain Buy Buy
2023-11-06 Piper Sandler Maintain Overweight Overweight
2023-11-03 Goldman Sachs Maintain Buy Buy
2023-11-02 JP Morgan Maintain Overweight Overweight
2023-11-02 Barclays Maintain Overweight Overweight
2023-10-30 Stifel Maintain Hold Hold
2023-09-15 Stifel Maintain Hold Hold
2023-08-03 Morgan Stanley Maintain Overweight Overweight
2023-08-02 Atlantic Equities Downgrade Overweight Neutral
2023-08-02 JP Morgan Maintain Overweight Overweight
2023-06-07 Atlantic Equities Maintain Overweight Overweight
2023-05-03 Atlantic Equities Maintain Overweight Overweight
2023-03-23 Morgan Stanley Maintain Overweight Overweight
2023-02-08 Barclays Maintain Overweight Overweight
2023-02-07 Atlantic Equities Maintain Overweight Overweight
2023-02-07 JP Morgan Maintain Overweight Overweight
2023-01-25 Goldman Sachs Maintain Buy Buy
2022-11-15 Morgan Stanley Maintain Overweight Overweight
2022-11-02 Atlantic Equities Maintain Overweight Overweight
2022-10-17 JP Morgan Maintain Overweight Overweight
2022-08-05 Barclays Maintain Overweight Overweight
2022-08-04 Morgan Stanley Maintain Overweight Overweight
2022-08-03 Atlantic Equities Maintain Overweight Overweight
2022-07-26 Piper Sandler Maintain Overweight Overweight
2022-07-25 Stifel Downgrade Buy Hold
2022-07-21 Goldman Sachs Upgrade Neutral Buy
2022-07-12 Piper Sandler Maintain Overweight Overweight
2022-06-24 Stifel Maintain Buy Buy
2022-05-19 Goldman Sachs Maintain Neutral Neutral
2022-05-05 B of A Securities Downgrade Buy Neutral
2022-05-05 Morgan Stanley Maintain Overweight Overweight
2022-02-08 Atlantic Equities Maintain Overweight Overweight
2021-11-18 Morgan Stanley Maintain Overweight Overweight
2021-08-13 Credit Suisse Maintain Outperform Outperform
2021-08-03 Goldman Sachs Maintain Neutral Neutral
2021-08-02 Barclays Maintain Overweight Overweight
2021-07-12 Guggenheim Downgrade Buy Neutral
2021-02-17 Barclays Maintain Overweight Overweight
2021-01-29 JP Morgan Maintain Overweight Overweight
2020-08-17 Credit Suisse Maintain Outperform Outperform
2020-07-30 Stifel Maintain Buy Buy
2020-07-20 B of A Securities Maintain Buy Buy
2020-05-01 Stifel Maintain Buy Buy
2019-09-09 Goldman Sachs Maintain Neutral Neutral
2019-08-16 Credit Suisse Maintain Outperform Outperform
2019-07-22 Stifel Maintain Buy Buy
2019-07-22 Stifel Nicolaus Maintain Buy Buy
2019-05-23 Guggenheim Maintain Buy Buy
2019-05-02 Canaccord Genuity Maintain Buy Buy
2018-11-05 Canaccord Genuity Maintain Buy Buy
2018-11-02 B of A Securities Maintain Buy Buy
2018-11-02 Bank of America Maintain Buy Buy
2018-08-17 Credit Suisse Maintain Outperform Outperform
2018-07-10 Stifel Maintain Buy Buy
2018-07-10 Stifel Nicolaus Maintain Buy Buy
2018-06-21 Credit Suisse Maintain Outperform Outperform
2018-06-01 Credit Suisse Maintain Outperform Outperform
2018-05-07 Stifel Nicolaus Maintain Buy Buy
2018-05-07 Stifel Maintain Buy Buy
2018-02-02 B of A Securities Maintain Buy Buy
2018-02-02 Bank of America Maintain Buy Buy
2018-01-16 PiperJaffray Maintain Overweight Overweight
2017-08-23 B of A Securities Upgrade Neutral Buy
2017-08-23 Bank of America Upgrade Neutral Buy
2017-06-01 Aegis Capital Maintain Sell Sell
2016-04-13 Credit Suisse Maintain Outperform Outperform
2016-04-01 CL King Maintain Neutral Neutral
2016-03-21 Stifel Maintain Buy Buy
2016-03-21 Stifel Nicolaus Maintain Buy Buy
2016-02-03 Credit Suisse Maintain Outperform Outperform
2015-08-28 Raymond James Downgrade Outperform Market Perform
2015-07-23 Feltl & Co. Upgrade Sell Hold
2015-04-29 Stifel Nicolaus Maintain Buy Buy
2015-04-29 Stifel Maintain Buy Buy
2015-04-28 Canaccord Genuity Maintain Buy Buy
2015-01-16 Stifel Nicolaus Maintain Buy Buy
2015-01-16 Stifel Maintain Buy Buy
2014-10-28 Canaccord Genuity Maintain Buy Buy
2014-10-27 Stifel Maintain Buy Buy
2014-10-27 Stifel Nicolaus Maintain Buy Buy
2014-06-24 Canaccord Genuity Upgrade Hold Buy
2014-01-30 Feltl & Co. Downgrade Hold Sell
2013-04-23 Canaccord Genuity Maintain Hold Hold
2013-01-29 Canaccord Genuity Maintain Hold Hold
2012-11-08 Stifel Nicolaus Maintain Hold Hold
2012-08-28 Canaccord Genuity Maintain Hold Hold
2012-04-23 Feltl & Co. Maintain Hold Hold
2012-04-20 Bank oferica Maintain Buy Buy
2012-04-20 B of A Securities Maintain Buy Buy
2012-03-15 Feltl & Co. Maintain Hold Hold